Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Haploidentical Donor HCT
NCT02750254Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in graft-versus-host disease (GVHD), sponsored by Washington University School of Medicine. Primary endpoints: Safety of azacitidine as measured by frequency and grade of adverse events, Maximum tolerated dose of azacitidine and 1 more. Started Jun 2016; status: terminated.
02
Drugs
azacitidine
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02750254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750254.